Currently, 2 biologic therapies are available for the treatment of moderate‐to‐severe AD: dupilumab—an IL‐4 receptor α antibody that blocks IL‐4 and IL‐13 signaling—and tralokinumab. This evidence concerns the gene IL13 and Alzheimer disease.